Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 5, 2004, Pages 754-762

  Madoiwa, S ^a   Yamauchi, T ^a   Hakamata, Y ^a   Kobayashi, E ^a   Arai, M ^b   Sugo, T ^a   Mimuro, J ^a   Sakata, Yoichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Factor VIII deficient mice; Hemophilia A; Immune tolerance; Neonate

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 2; RECOMBINANT BLOOD CLOTTING FACTOR 8; TETANUS TOXOID; TOXIN ANTIBODY;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BIRTH; BODY WEIGHT; CELL PROLIFERATION; CELL STIMULATION; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; HEMOPHILIA A; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INTERFERON PRODUCTION; INTERMETHOD COMPARISON; LYMPHOCYTE PROLIFERATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PUERPERIUM; SPLEEN CELL; SUBSTITUTION THERAPY; T LYMPHOCYTE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, HETEROPHILE; BLOOD COAGULATION; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INJECTIONS, INTRAVENOUS; MICE; MICE, KNOCKOUT; SPLEEN; T-LYMPHOCYTES; TIME FACTORS;

EID: 13244277737     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7933.2004.00671.x     Document Type: Article

References (48)

1. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
2. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
3. Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost 1995; 21: 382-9.
4. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
5. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150-7.
6. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
7. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603-6.
8. Etlinger HM, Chiller JM. Maturation of the lymphoid system. I. Induction of tolerance in neonates with a T-dependent antigen that is an obligate immunogen in adults. J Immunol 1979; 122: 2558-63.
9. Etlinger HM, Chiller JM. Maturation of the lymphoid system. II. Characterization of the cellular levels of unresponsiveness induced in neonates by a T-dependent antigen that is an obligate immunogen in adults. J Immunol 1979; 122: 2564-70.
10. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity in neonatal mice. Science 1996; 271: 1728-30.
11. Gammon G, Dunn K, Shastri N, Oki A, Wilbur S, Sercarz EE. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation. Nature 1986; 319: 413-5.
12. Sarzotti M, Robbins DS, Hoffman PM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 1996; 271: 1726-8.
13. Dazzi F, Rosato A, Tison T, Vianello F, Radossi P. An animal model to explore the molecular basis of factor VIII (FVIII) inhibitor formation: evidence of anti-FVIII T-cell response and importance of administration route. Thromb Haemost 1995; 73: 1026.
14. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
15. Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH Jr. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
16. Hausl C, Maier E, Schwarz HP, Ahmad RU, Turecek PL, Dorner F, Reipert BM. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-5.
17. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
18. Qian J, Borovok M, Bi L, Kazazian HH Jr, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
19. Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A, Kaleko M. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
20. Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001; 7: 242-9.
21. Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
22. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-32.
23. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
24. Kruisbeek AM, Shevach E. Proliferative assays for T Cell function. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. Unit 3.12. New York: Wiley, 1996: 1-12.
25. Min B, Legge KL, Pack C, Zaghouani H. Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy. J Exp Med 1998; 188: 2007-17.
26. Min B, Legge KL, Bell JJ, Gregg RK, Li L, Caprio JC, Zaghouani H. Neonatal exposure to antigen induces a defective CD40 ligand expression that undermines both IL-12 production by APC and IL-2 receptor up-regulation on splenic T cells and perpetuates IFN-gamma-dependent T cell anergy. J Immunol 2001; 166: 5594-603.
27. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, Vitetta ES. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988; 334: 255-8.
28. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46 111-47.
29. Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
30. Kavanagh ML, Wood CN, Davidson JF. The immunological characterization of human antibodies to factor VIII isolated by immunoaffinity chromatography. Thromb Haemost 1981; 45: 60-4.
31. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
32. Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-32.
33. Nossal GJ. Cellular mechanisms of immunologic tolerance. Annu Rev Immunol 1983; 1: 33-62.
34. Loblay RH, Fazekas de St Groth B, Pritchard-Briscoe H, Basten A. Suppressor T cell memory. II. The role of memory suppressor T cells in tolerance to human gamma globulin. J Exp Med 1983; 157: 957-73.
35. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81 2925-35.
36. Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science 1992; 257: 539-42.
37. Pfeiffer C, Murray J, Madri J, Bottomly K. Selective activation of Th1- and Th2-like cells in vivo - response to human collagen IV. Immunol Rev 1991; 123: 65-84.
38. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995; 182 1579-84.
39. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-73.
40. Jenkins MK, Pardoll DM, Mizuguchi J, Quill H, Schwartz RH. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 1987; 95: 113-35.
41. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 1997; 185: 817-24.
42. Van Parijs L, Perez VL, Biuckians A, Maki RG, London CA, Abbas AK. Role of interleukin 12 and costimulators in T cell anergy in vivo. J Exp Med 1997; 186: 1119-28.
43. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
44. Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA, Brown SA. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
45. Haya S, Lorenzo JI, Dasi MA, Aznar JA. Development of a factor VIII inhibitor in a newborn haemophiliac. Haemophilia 1998; 4: 755-6.
46. VandenDriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen ML, Collen D, Chuah MK. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379-84.
47. Waddington SN, Buckley SM, Nivsarkar M, Jezzard S, Schneider H, Dahse T, Kemball-Cook G, Miah M, Tucker N, Dallman MJ, Themis M, Coutelle C. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood 2003; 101: 1359-66.
48. Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999; 21: 289-95.